EI

265.7

-0.26%↓

SAN

86.43

-0.1%↓

MRK1

109.1

+1.21%↑

SHL.DE

47.57

+0.51%↑

ARGX

589.8

-2.71%↓

EI

265.7

-0.26%↓

SAN

86.43

-0.1%↓

MRK1

109.1

+1.21%↑

SHL.DE

47.57

+0.51%↑

ARGX

589.8

-2.71%↓

EI

265.7

-0.26%↓

SAN

86.43

-0.1%↓

MRK1

109.1

+1.21%↑

SHL.DE

47.57

+0.51%↑

ARGX

589.8

-2.71%↓

EI

265.7

-0.26%↓

SAN

86.43

-0.1%↓

MRK1

109.1

+1.21%↑

SHL.DE

47.57

+0.51%↑

ARGX

589.8

-2.71%↓

EI

265.7

-0.26%↓

SAN

86.43

-0.1%↓

MRK1

109.1

+1.21%↑

SHL.DE

47.57

+0.51%↑

ARGX

589.8

-2.71%↓

Search

UCB SA

Suletud

SektorTervishoid

201.7 1.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

199.3

Max

202.4

Põhinäitajad

By Trading Economics

Sissetulek

857M

Müük

3.4B

P/E

Sektori keskmine

28.533

35.473

Dividenditootlus

0.72

Kasumimarginaal

25.498

Töötajad

8,600

EBITDA

1.3B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+19.23% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.72%

2.38%

Turustatistika

By TradingEconomics

Turukapital

1.8B

37B

Eelmine avamishind

200.57

Eelmine sulgemishind

201.7

Uudiste sentiment

By Acuity

50%

50%

181 / 372 Pingereas Healthcare

UCB SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. juuli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

Võrdlus sarnastega

Hinnamuutus

UCB SA Prognoos

Hinnasiht

By TipRanks

19.23% tõus

12 kuu keskmine prognoos

Keskmine 94.86 EUR  19.23%

Kõrge 125 EUR

Madal 74 EUR

Põhineb 7 Wall Streeti analüütiku instrumendi UCB SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

4

Osta

1

Hoia

2

Müü

Sentiment

By Acuity

181 / 372 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.